{"disease":{"id":"kras-g12d","name":"kras g12d"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06500676","title":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":407,"lead_sponsor_name":"Genfleet Therapeutics (Shanghai) Inc.","has_results":false},{"nct_id":"NCT07023731","title":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":159,"lead_sponsor_name":"Arvinas Inc.","has_results":false},{"nct_id":"NCT06218914","title":"Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05533463","title":"Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT07303465","title":"To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Ranok Therapeutics (Hangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07456046","title":"A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"D3 Bio (Wuxi) Co., Ltd","has_results":false},{"nct_id":"NCT06546150","title":"RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03608631","title":"iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07342738","title":"TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04853017","title":"A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Elicio Therapeutics","has_results":true},{"nct_id":"NCT05631899","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07083479","title":"Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Elicio Therapeutics","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}